Automation and contamination-control demand drives pharma manufacturing equipment markets to 2035

The Pharma Robots market and the Clean Room Pass Through market are projected to expand through 2035 as pharmaceutical manufacturing strategy shifts toward automation and contamination control. The global Pharma Robots market is poised for a transformative decade, while the Clean Room Pass Through market size was valued at USD 988.97 million in 2025 and is projected to reach USD 1878.67 million by 2035, growing at a CAGR of 6.65% during 2026-2035.

According to the latest market analysis, the global Pharma Robots market enters 2026 with broader demand fundamentals, more disciplined procurement behavior, and a more regionally diversified supply architecture. The market is forecast to expand from 2026 to 2035, underpinned by the escalating complexity of drug modalities, particularly cell and gene therapies and biologics, which demand unprecedented levels of precision and sterility. Growth is further accelerated by persistent skilled labor shortages, intensifying cost pressures, and a global regulatory push toward Industry 4.0 and data integrity.

In sterile manufacturing, this segment represents the largest and most critical application, driven by the absolute necessity to maintain sterility in injectable drugs, vaccines, and biologics. Through 2035, demand will accelerate due to the rising volume of parenteral biologics and the updated EU GMP Annex 1, which strongly advocates for automation to minimize human intervention. Major trends include adoption of robotic isolators over manual operations for higher sterility assurance level, integration of advanced machine vision for 100% inline inspection, flexible modular systems capable of quick changeover between different container formats, and growing use of collaborative robots for secondary tasks like tray loading and palletizing within the cleanroom.

The Clean Room Pass Through market is expanding with the rising demand for contamination control in the pharmaceutical, biotech, medical devices, and electronics industries. Strict regulatory standards and compliance requirements from agencies like the FDA and EMA are pushing manufacturers to implement pass-through systems for continuous sterile environments, while rapid adoption of dynamic and automated pass-through systems enhances operational efficiency, reduces cross-contamination risks, and supports precision cleanroom processes globally.

Globally, more than 8,000 bio/pharmaceutical cleanrooms are in use today, and this number is projected to grow further with expanding biologics and gene therapy production facilities. The U.S. Clean Room Pass Through market size was valued at USD 258.69 million in 2025 and is projected to reach USD 475.95 million by 2035, growing at a CAGR of 6.31% during 2026-2035. Emerging economies in Asia Pacific, Latin America, and the Middle East are also expected to drive demand because of rising investments in pharmaceuticals and electronics manufacturing infrastructure.

For pharma robots, the baseline scenario through 2035 is one of sustained, above-GDP growth, moving beyond recovery from post-pandemic capital expenditure cycles into a new phase of structural adoption. The adoption curve will be steepest in greenfield facilities in Asia-Pacific and strategic retrofits in established biotech hubs in North America and Europe. For clean room pass-through systems, high initial costs involved with installation and ongoing regular maintenance, coupled with highly stringent compliance requirements, remain restraints on growth.